重新利用黄皮醇作为肺纤维化治疗的吸入治疗药物
Ching-Hsien Chen1, Subash K Chaudhary2, Wen-Hsin Chang1
1Department of Internal Medicine, University of California, Davis, CA, 95616, USA.
European journal of pharmacology
|August 15, 2025
概括
循环素依赖性激酶9 (CDK9) 抑制在治疗异常性肺纤维化 (IPF) 方面显示出前景. 一种CDK9抑制剂flavopiridol在临床前模型中减少了肺纤维化,为这种渐进的肺病提供了潜在的新疗法.
科学领域:
- 肺部病理学 肺部病理学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性肺病,治疗选择很少.
- 循环素依赖酶9 (CDK9) 是一种转录调节剂,与纤维性疾病有关.
- 目前没有针对IPF的CDK9向疗法.
研究的目的:
- 为了研究CDK9在IPF病变发生中的作用.
- 为了评估CDK9抑制使用flavopiridol治疗IPF的治疗潜力.
主要方法:
- 在IPF肺纤维细胞中评估CDK9表达.
- 用flavopiridol处理的IPF肺纤维细胞和精密切割的肺切片.
- 在白胺诱导的肺纤维化小鼠模型中评估了flavopiridol的疗效.
- 开发并测试了一种可吸入的flavopiridol配方.
主要成果:
- 在IPF肺纤维细胞中,CDK9表达升高,与纤维化标志物相关.
- 黄皮醇在体外和体外表现出显著的抗纤维素作用.
- 系统性flavopiridol改善了小鼠的生存率和减少了肺纤维化,表现优于nintedanib.
- 吸入式flavopiridol减轻了肺纤维化,减少了全身暴露.
结论:
- CDK9是肺纤维化的一个关键调节剂.
- CDK9抑制剂,如黄皮醇,是IPF的一种有前途的新疗法策略.
- 通过吸入进行局部输送可能会提高IPF的CDK9抑制剂的安全性和有效性.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
01:26COPD: Management Using Bronchodilators and Corticosteroids
310
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
310
01:23Inhaled Medications
389
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
389
01:17Drugs Used in Lower Respiratory Disorders: Overview
583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
250
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
250
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K